Rebamipide AND Sjögren Syndrome

• Status: Recruiting
• Trial end date: 2021-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Xerostomia is a major distressing symptom in Sjőgren's syndrome(SS). Preclinical and clinical studies have demonstrated an increase in saliva volume following rebamipide administration.We thus hypothesize that rebamipide may be efficacious in the treatment of dry mouth symptoms related to Sjőgren's syndrome.We will recruit SS patients in a randomized placebo-controlled trial for 12 weeks. The main outcome measure that will concern us is patient-assessed improvement of dry mouth symptoms and increase in salivary secretion Safety and efficacy was assessed at each visit.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Faculty of Medicine, University of Alexandria; University of Alexandria
• Treatments: Rebamipide

Criteria

Inclusion Criteria:

• SS patients with dry mouth symptoms

Exclusion Criteria:

• Patients with dry mouth due to other conditions